RAI Administration in Thyroid Cancer Patients with Multiple Sclerosis
Administer radioiodine therapy for thyroid cancer in patients with multiple sclerosis using the standard protocols (100-200 mCi depending on indication), but prepare the patient with recombinant human TSH (rhTSH) instead of thyroid hormone withdrawal to avoid exacerbating MS symptoms through prolonged hypothyroidism. 1
Rationale for rhTSH Preparation
The critical issue in this clinical scenario is avoiding thyroid hormone withdrawal, which induces profound hypothyroidism for 3-4 weeks. This metabolic state can significantly worsen MS symptoms, trigger relapses, and impair quality of life in MS patients. The French guidelines explicitly address this concern, stating that rhTSH may be used off-label when there is "risk of poor tolerance of hypothyroidism" 1. Multiple sclerosis clearly falls into this category, as hypothyroidism can:
- Worsen fatigue (already a cardinal MS symptom)
- Impair cognitive function and mobility
- Potentially trigger MS exacerbations
- Significantly compromise quality of life during the preparation period
Standard RAI Dosing Applies
The presence of MS does not alter the therapeutic RAI doses needed for thyroid cancer:
For Remnant Ablation
For Adjuvant Therapy
- 100 mCi (3.7 GBq) for intermediate-risk disease 1
- May range from 30-150 mCi depending on risk stratification 3
For Metastatic Disease
- 100-200 mCi (3.7-7.4 GBq) per treatment cycle 1
- Bone metastases: 100-200 mCi with local consolidation as needed 1
- Pulmonary metastases: 100-200 mCi, repeated every 6 months if RAI-avid 1
Treatment Protocol Modifications
Key modification: Validate the rhTSH preparation approach through multidisciplinary team meeting, as this represents off-label use 1. The guideline specifically recommends this validation step when deviating from standard thyroid hormone withdrawal protocols.
Preparation Steps:
- Coordinate with neurology to optimize MS disease-modifying therapy timing
- Obtain multidisciplinary approval for rhTSH use
- Administer rhTSH 0.9 mg IM on days 1 and 2
- Give RAI on day 3 or 4
- Maintain patient on thyroid hormone replacement throughout
Important Caveats
Efficacy consideration: While rhTSH preparation is slightly less effective than thyroid hormone withdrawal for achieving maximal TSH stimulation, the difference is clinically insignificant for most patients 1. The preservation of quality of life and prevention of MS exacerbation clearly outweighs any marginal reduction in RAI uptake.
Contraindications to monitor: The standard iodine contraindications still apply - check for iododerma history, active tuberculosis, and laryngeal edema 4. MS itself is not a contraindication to RAI therapy.
Repeat treatments: If multiple RAI cycles are needed for persistent disease, continue using rhTSH preparation for each cycle 1. The 6-month interval between treatments for metastatic disease allows adequate time for MS stability assessment.
Risk-Benefit Analysis
The 2025 NCCN guidelines emphasize that RAI should be considered for "clinically progressive or symptomatic RAI-refractory DTC" with kinase inhibitors showing clinical benefit in 50-60% of patients 2. However, for RAI-avid disease, radioiodine remains superior to systemic therapy. The presence of MS should not prevent appropriate RAI treatment when indicated - it simply requires modification of the preparation protocol to protect neurological function.